Advertisement
Advertisement

CLRB

CLRB logo

Cellectar Biosciences INC NEW

2.95
USD
Sponsored
-0.03
-1.16%
Mar 25, 15:58 UTC -4
Closed
exchange

Pre-Market

2.98

+0.02
+0.85%

CLRB Earnings Reports

Positive Surprise Ratio

CLRB beat 20 of 39 last estimates.

51%

Next Report

Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/
-$2.41
Implied change from Q4 25 (Revenue/ EPS)
--
/
+86.82%
Implied change from Q1 25 (Revenue/ EPS)
--
/
-42.62%

Cellectar Biosciences INC NEW earnings per share and revenue

On Mar 04, 2026, CLRB reported earnings of -1.29 USD per share (EPS) for Q4 25, beating the estimate of -2.33 USD, resulting in a 44.85% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +8.21% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -2.41 USD, with revenue projected to reach -- USD, implying an increase of 86.82% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Cytosorbents Corp.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.09
Surprise
-76.47%
logo
Nephros Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.01
Actual
$0.08
Surprise
+684.31%
logo
Capricor Therapeutics Inc
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.62
Surprise
-12.56%
logo
Kestra Medical Technologies, Ltd. Common Stock
Report Date
Mar 17, 2026 For Q3 26
Estimate
-$0.60
Actual
-$0.61
Surprise
-0.39%
logo
Sundial Growers Inc. Common Shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.01
Actual
$0.04
Surprise
+499.62%
logo
High Tide Inc. Common Shares
Report Date
Mar 17, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+447.68%
logo
Sanara MedTech Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.11
Actual
$0.04
Surprise
-64.35%
FAQ
For Q4 2025, Cellectar Biosciences INC NEW reported EPS of -$1.29, beating estimates by 44.85%, and revenue of $0.00, 0% as expectations.
The stock price moved up 8.21%, changed from $2.68 before the earnings release to $2.90 the day after.
The next earning report is scheduled for May 11, 2026.
Based on 5 analysts, Cellectar Biosciences INC NEW is expected to report EPS of -$2.41 and revenue of -- for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement